Not surprisingly, the reviews are mixed
Diabetologia 67(3):561566
March 9, 2026: Novo Nordisk Resolves Ozempic Knockoff Lawsuit with Competitor Novo Nordisk has resolved a legal disagreement with U.S
Several GLP-1 agonists have FDA approval for other indications that may overlap with BED patient populations: Semaglutide (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are approved for type 2 diabetes management Tirzepatide (Zepbound) is approved for chronic weight management When clinicians prescribe GLP-1 agonists for BED, this constitutes off-label use a legal and common practice in medicine when evidence suggests potential benefit and approved treatments are inadequate
You can access your Patient Portal in the navigation at the top of this page labeled Patient Login or you can access your Patient Portal here
Some of these will be mild, like flatulence, cramping, or constipation, whilst others can be more severe
